Prostate Cancer (PC)

Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Prostate Cancer

MalaCards integrated aliases for Prostate Cancer:

Name: Prostate Cancer 57 11 42 73 53 41 2 14 36 63 75 33
Prostate Carcinoma 11 42 53 14 16 71
Prostate Cancer, Familial 57 11 19 75 71
Prostate Neoplasm 11 42 28 5
Prostate Cancer, Susceptibility to 57 28 5
Prostate Cancer, Somatic 57 28 5
Prostatic Neoplasms 53 43 71
Prostatic Cancer 11 42 14
Malignant Neoplasm of Prostate 71 31
Familial Prostate Carcinoma 28 5
Malignant Tumor of Prostate 28 5
Hereditary Prostate Cancer 11 19
Familial Prostate Cancer 19 58
Carcinoma of Prostate 11 33
Prostatic Neoplasm 11 42
Cancer of Prostate 11 33
Prostate Cancer, Familial, Susceptibility to 57
Primary Malignant Neoplasm of Prostate 33
Malignant Neoplasm of the Prostate 42
Malignant Tumor of the Prostate 11
Ngp - New Growth of Prostate 11
Malignant Tumour of Prostate 33
Prostate Cancer, Hereditary 19
Malignant Prostatic Tumour 33
Primary Prostate Cancer 33
Cancer of the Prostate 42
Tumor of the Prostate 11
Prostate Gland Cancer 33
Prostatic Carcinoma 42
Cancer, Prostate 38
Prca 73
Pc 73



Somatic mutation 57


Familial Prostate Cancer: 1-9/100000 (United States) 58

Age Of Onset:

Familial Prostate Cancer: Adult 58


Orphanet: 58  
Rare urogenital diseases

External Ids:

Disease Ontology 11 DOID:10283 DOID:10286
OMIM® 57 176807
ICD9CM 34 185
MeSH 43 D011471
ICD10 31 C61
MESH via Orphanet 44 C537243
ICD10 via Orphanet 32 C61
UMLS via Orphanet 72 C2931456
Orphanet 58 ORPHA1331
MedGen 40 C0376358
SNOMED-CT via HPO 69 399068003
UMLS 71 C0033578 C0376358 C0600139 more

Summaries for Prostate Cancer

MedlinePlus: 41 What is prostate cancer? Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen. Prostate cancer is one of the most common types of cancer. It often grows very slowly. If it does not spread to other parts of the body, it may not cause serious problems. But sometimes prostate cancer can grow quickly and spread to other parts of the body. This kind of prostate cancer is serious. What causes prostate cancer? Researchers don't know for sure what causes prostate cancer. They do know that it happens when there are changes in the genetic material (DNA). Sometimes these genetic changes are inherited, meaning that you are born with them. There are also certain genetic changes that happen during your lifetime that can raise your risk of prostate cancer. But often the exact cause of these genetic changes is unknown. Who is more likely to develop prostate cancer? Anyone who has a prostate can develop prostate cancer. But certain factors can make you more likely to develop it: Age. Your chance of developing prostate cancer increases as you get older. Prostate cancer is rare in people under age 50. Family health history. Your risk of prostate cancer is higher if you have a parent, sibling, or child who has or has had prostate cancer. Race. African Americans are more likely to get prostate cancer. They're also more likely to: Get prostate cancer at a younger age. Have more serious prostate cancer. Die from prostate cancer. What are the symptoms of prostate cancer? Prostate cancer doesn't always cause symptoms, especially at first. If it does cause symptoms, they may include: Problems urinating (peeing), such as: A urine stream that's weak, hard to start, or starts and stops Suddenly needing to urinate right away Urinating often, especially at night Pain or burning when urinating Blood in your urine or semen Pain in your lower back, hips, or pelvis that does not go away Painful ejaculation (the release of semen through the penis during orgasm) But many of these symptoms may be from other common prostate problems that aren't cancer, such as an enlarged prostate. You should discuss your prostate health with your health care provider if you: Have symptoms that could be prostate cancer Have a high risk for developing prostate cancer Had a screening test that suggests you could have prostate cancer What are prostate tests and how is prostate cancer diagnosed? Tests which check for prostate cancer include: A digital rectal exam (DRE). In this exam, your provider feels your prostate for lumps or anything unusual by inserting a lubricated, gloved finger into your rectum. A prostate-specific antigen (PSA) blood test. A high PSA blood level may be a sign of prostate cancer. But many other things can cause high PSA levels, too. Imaging tests. These tests may use ultrasound or MRI to make pictures of your prostate. If these tests show that you might have prostate cancer, the next step is usually a prostate biopsy. A biopsy is the only way to diagnose prostate cancer. During a biopsy, a doctor uses a hollow needle to remove some prostate tissue. The tissue is studied under a microscope to look for cancer cells. What are the treatments for prostate cancer? Your treatment options usually depend on your age, your general health, and how serious the cancer is. Your treatment may include one or more of options: Observation,which is mostly used if you are older, your prostate cancer isn't likely to grow quickly, and you don't have symptoms or you have other medical conditions. Your doctor will keep checking on your cancer over time so to see whether you will need to start treatment for the cancer. There are two types of observation: Watchful waiting means having little or no testing. If symptoms begin or change, you will get treatment to relieve them, but not to treat the cancer. Active surveillance means having regular tests to see if your prostate cancer has changed. If the tests show the cancer is starting to grow or if you develop symptoms, then you will have treatment to try to cure the cancer. Surgery to remove your prostate gland may be an option if your cancer hasn't spread outside of your prostate. Radiation therapy uses high energy to kill cancer cells or prevent them from growing. Hormone therapy blocks cancer cells from getting the hormones they need to grow. It may include taking medicines or having surgery to remove the testicles. Chemotherapy uses medicines to kill cancer cells, slow their growth, or stop them from spreading. You might take the drugs by mouth, as an injection (shot), as a cream, or intravenously (by IV). Targeted therapy uses drugs or other substances that attack specific cancer cells. This treatment causes less harm to healthy cells than radiation therapy or chemotherapy. Immunotherapy helps your own immune system to fight cancer. Can prostate cancer be prevented? Making healthy lifestyle changes may help to prevent some prostate cancers. These changes include: Being at a healthy weight Quitting smoking Getting enough exercise Eating healthy foods NIH: National Cancer Institute

MalaCards based summary: Prostate Cancer, also known as prostate carcinoma, is related to breast cancer and prostate disease, and has symptoms including tremor, angina pectoris and equilibration disorder. An important gene associated with Prostate Cancer is CHEK2 (Checkpoint Kinase 2), and among its related pathways/superpathways are Endometrial cancer and Breast cancer pathway. The drugs Sodium citrate and Sildenafil have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and lymph node, and related phenotypes are prostate cancer and neoplasm

MedlinePlus Genetics: 42 Prostate cancer is a common disease that affects men, usually in middle age or later. In this disorder, certain cells in the prostate become abnormal, multiply without control or order, and form a tumor. The prostate is a gland that surrounds the male urethra and helps produce semen, the fluid that carries sperm.Early prostate cancer usually does not cause pain, and most affected men exhibit no noticeable symptoms. Men are often diagnosed as the result of health screenings, such as a blood test for a substance called prostate specific antigen (PSA) or a medical exam called a digital rectal exam (DRE). As the tumor grows larger, signs and symptoms can include difficulty starting or stopping the flow of urine, a feeling of not being able to empty the bladder completely, blood in the urine or semen, or pain with ejaculation. However, these changes can also occur with many other genitourinary conditions. Having one or more of these symptoms does not necessarily mean that a man has prostate cancer.The severity and outcome of prostate cancer varies widely. Early-stage prostate cancer can usually be treated successfully, and some older men have prostate tumors that grow so slowly that they may never cause health problems during their lifetime, even without treatment. In other men, however, the cancer is much more aggressive; in these cases, prostate cancer can be life-threatening.Some cancerous tumors can invade surrounding tissue and spread to other parts of the body. Tumors that begin at one site and then spread to other areas of the body are called metastatic cancers. The signs and symptoms of metastatic cancer depend on where the disease has spread. If prostate cancer spreads, cancerous cells most often appear in the lymph nodes, bones, lungs, liver, or brain. A small percentage of prostate cancers are hereditary and occur in families. These hereditary cancers are associated with inherited gene variants. Hereditary prostate cancers tend to develop earlier in life than non-inherited (sporadic) cases.

GARD: 19 Familial prostate cancer is a cluster of prostate cancer within a family. Most cases of prostate cancer occur sporadically in people with no family history of the condition. However, approximately 5% to 10% of prostate cancer cases are believed to be primarily caused by a genetic predisposition to the condition. In many families, the underlying genetic cause is unknown; however, some of these cases are caused by changes in the BRCA1, BRCA2, HOXB13, or several other genes. Other cases are likely due to a combination of gene(s) and other shared factors such as environment and lifestyle. High-risk cancer screening at an earlier age is typically recommended in men who have an increased risk for prostate cancer based on personal and/or family histories.

Novus Biologicals: 54 Prostate cancer is the most common non-skin cancer and second most deadly cancer for men in the United States. Prostate cancer occurs when cells within the prostate grow uncontrollably and create small tumors. If untreated, cells from these tumors can spread via metastasis. Metastasis transports prostate cancer cells through the lymphatic system and bloodstream to other parts of the body where they can grow into secondary tumors. PSA, a protein produced by the prostate, is released into the bloodstream in small amounts under normal conditions. However, PSA is released in increasing amounts when the prostate is malfunctioning, as is the case with prostate cancer.

PubMed Health : 63 Prostate cancer: Prostate cancer develops when cells in the prostate start multiplying uncontrollably. This can happen if the genetic information (DNA) in the cells has changed (mutated). The body’s immune system usually keeps these cells in check. Cancer develops if too many mutated cells multiply and a tumor grows. The diagnosis “prostate cancer” usually comes as a shock to men and those close to them. The good news is that prostate cancer is one of the types of cancer with the best chances of recovery. This is because it often grows very slowly so it is generally possible to treat it effectively.

UniProtKB/Swiss-Prot: 73 A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.

Orphanet: 58 Familial prostate cancer (FPC) is a malignant tumor of the prostate with an early onset. FPC is either asymptomatic or causes mictionary symptoms, erectile dysfunction, bone pain, venous compression and infectious or inflammatory syndrome (for the metastatic forms). It is also characterized by familial antecedents.

CDC: 2 Cancer is a disease in which cells in the body grow out of control. When cancer starts in the prostate, it is called prostate cancer. Not including skin cancer, prostate cancer is the most common cancer in American men.

Disease Ontology 11 Prostate cancer: A male reproductive organ cancer that is located in the prostate.

Prostate carcinoma: A prostate cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

Wikipedia: 75 Prostate cancer is cancer of the prostate. Prostate cancer is the second most common cancerous tumor... more...

More information from OMIM: 176807

Related Diseases for Prostate Cancer

Diseases in the Prostate Cancer family:

Prostate Cancer, Hereditary, 1 Prostate Cancer, Hereditary, 8
Prostate Cancer, Hereditary, 3 Prostate Cancer, Hereditary, 4
Prostate Cancer, Hereditary, 5 Prostate Cancer, Hereditary, 6
Prostate Cancer, Hereditary, 7 Prostate Cancer, Hereditary, 9
Prostate Cancer, Hereditary, 10 Prostate Cancer, Hereditary, 12
Prostate Cancer, Hereditary, 13 Prostate Cancer, Hereditary, 11
Prostate Cancer, Hereditary, 14 Prostate Cancer, Hereditary, 15
Prostate Cancer, Hereditary, 2 Prostate Carcinoma in Situ

Diseases related to Prostate Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1897)
# Related Disease Score Top Affiliating Genes
1 breast cancer 34.3 ZFHX3 TP53 PTEN POLK MIR222 MIR221
2 prostate disease 33.8 MIR222 MIR221 MIR21 MIR205 MIR17 MIR146A
3 suppression of tumorigenicity 12 33.6 TP53 PTEN MIR221 MIR145 KLF6 CDH1
4 ovarian cancer 33.2 TP53 PTEN MIRLET7C MIR222 MIR221 MIR21
5 bladder cancer 33.1 TP53 PTEN MIR222 MIR221 MIR21 MIR205
6 diffuse gastric and lobular breast cancer syndrome 33.1 TP53 PTEN CHEK2 CDH1 BRCA2
7 lung cancer 33.0 TP53 PTEN POLK MIRLET7C MIR222 MIR221
8 leukemia, acute myeloid 32.8 TP53 PTEN MIRLET7C MIR222 MIR221 MIR21
9 hepatocellular carcinoma 32.8 TP53 PTEN MIRLET7C MIR222 MIR221 MIR21
10 pancreatic cancer 32.7 TP53 PTEN MIR222 MIR221 MIR21 MIR205
11 melanoma 32.7 TP53 PTEN MIR222 MIR221 MIR21 MIR205
12 gastric cancer 32.6 ZFHX3 TP53 PTEN MIR222 MIR221 MIR21
13 body mass index quantitative trait locus 11 32.6 TP53 MIR222 MIR221 MIR21 MIR17 MIR146A
14 small cell carcinoma 32.6 TP53 PTEN MXI1 KLF6 HOXB13 CHEK2
15 inherited cancer-predisposing syndrome 32.6 TP53 PTEN CHEK2 CDH1 BRCA2
16 bap1 tumor predisposition syndrome 32.6 TP53 PTEN CHEK2 CDH1 BRCA2
17 lynch syndrome 32.5 TP53 PTEN MIR17 HOXB13 CHEK2 CDH1
18 renal cell carcinoma, nonpapillary 32.5 TP53 PTEN MIR222 MIR221 MIR21 MIR17
19 diabetes mellitus 32.5 TP53 PTEN MIR222 MIR21 MIR17 MIR146A
20 bone disease 32.5 MIR222 MIR221 MIR21 MIR17 MIR146A
21 skin carcinoma 32.5 TP53 PTEN MIR21 CDH1
22 hereditary breast ovarian cancer syndrome 32.5 TP53 PTEN HOXB13 CHEK2 BRCA2
23 peripheral nervous system disease 32.5 TP53 PTEN MIR21 MIR17 MIR146A MIR145
24 esophageal cancer 32.4 TP53 PTEN MIR222 MIR221 MIR21 MIR205
25 rectum cancer 32.4 TP53 MIR221 MIR21 MIR17 MIR145
26 colonic benign neoplasm 32.3 TP53 PTEN MIR21 MIR145 CHEK2 CDH1
27 lung cancer susceptibility 3 32.3 TP53 MIR21 MIR205 MIR17 MIR145 KLF6
28 glioblastoma 32.3 TP53 PTEN MIR222 MIR221 MIR21 KLF6
29 basal cell carcinoma 32.3 TP53 PTEN MXI1 KLF6 HOXB13 CHEK2
30 bone cancer 32.2 TP53 MIR222 MIR221 MIR21 MIR205 MIR17
31 brain cancer 32.2 TP53 PTEN MIR222 MIR221 MIR21 MIR17
32 endometrial cancer 32.2 TP53 PTEN MIR21 MIR145 CDH1 BRCA2
33 lymphatic system disease 32.2 TP53 MIR222 MIR221 MIR21 MIR205 MIR17
34 ataxia-telangiectasia 32.2 TP53 PTEN CHEK2 BRCA2
35 cardiovascular system disease 32.2 MIR222 MIR221 MIR21 MIR17 MIR146A MIR145
36 nasopharyngeal carcinoma 32.1 TP53 PTEN MIR21 MIR205 MIR17 MIR146A
37 kidney cancer 32.1 TP53 MIR21 MIR17 MIR145
38 squamous cell carcinoma, head and neck 32.1 TP53 PTEN MIR222 MIR221 MIR21 MIR205
39 leukemia, chronic lymphocytic 32.1 TP53 PTEN MIR221 MIR21 MIR17 MIR146A
40 neuroblastoma 32.0 TP53 PTEN MIR221 MIR21 MIR17 MIR145
41 rectal benign neoplasm 32.0 TP53 MIR17 MIR145
42 head and neck cancer 32.0 TP53 PTEN MIR222 MIR221 MIR21 MIR205
43 hematologic cancer 32.0 MIR222 MIR221 MIR21 MIR17 MIR146A MIR145
44 squamous cell carcinoma 32.0 TP53 PTEN MIRLET7C MIR205 CHEK2 CDH1
45 wilms tumor 1 32.0 TP53 PTEN CHEK2 CDH1 BRCA2
46 myeloma, multiple 31.9 TP53 MIR221 MIR21 MIR17 MIR145
47 cervical cancer 31.9 TP53 PTEN MIRLET7C MIR221 MIR21 MIR205
48 li-fraumeni syndrome 31.8 TP53 PTEN CHEK2 CDH1 BRCA2
49 diffuse gastric cancer 31.8 TP53 PTEN CHEK2 CDH1 BRCA2
50 adenoid cystic carcinoma 31.8 TP53 PTEN CHEK2 CDH1

Comorbidity relations with Prostate Cancer via Phenotypic Disease Network (PDN): (show all 35)

Acute Kidney Failure Anthracosis
Asbestosis Azoospermia
Balanoposthitis Bladder Cancer
Bladder Neck Obstruction Chronic Kidney Disease
Cystitis Cystica Deficiency Anemia
Disseminated Intravascular Coagulation Epididymo-Orchitis
Gout Hydronephrosis
Kidney Disease Lipoma of Spermatic Cord
Lymphadenitis Nephrolithiasis, X-Linked Recessive, with Renal Failure
Oligospermia Paralytic Ileus
Paraplegia Prostate Calculus
Prostate Carcinoma in Situ Prostate Disease
Prostatic Hypertrophy Prostatitis
Radiation Cystitis Spermatocele
Spinal Cord Disease Ureterolithiasis
Urethral Benign Neoplasm Urethral Calculus
Urethral Stricture Urethritis
Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Prostate Cancer:

Diseases related to Prostate Cancer

Symptoms & Phenotypes for Prostate Cancer

Human phenotypes related to Prostate Cancer:

# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 prostate cancer 30 HP:0012125

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
early onset prostate cancer

Clinical features from OMIM®:

176807 (Updated 08-Dec-2022)

UMLS symptoms related to Prostate Cancer:

tremor; angina pectoris; equilibration disorder

MGI Mouse Phenotypes related to Prostate Cancer:

# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.02 AR BRCA2 CDH1 CHEK2 MAD1L1 MIR146A
2 endocrine/exocrine gland MP:0005379 10 AR BRCA2 CDH1 CHEK2 HOXB13 KLF6
3 reproductive system MP:0005389 9.9 AR BRCA2 CDH1 CHEK2 HOXB13 KLF6
4 mortality/aging MP:0010768 9.8 AR BRCA2 CDH1 CHEK2 HOXB13 KLF6
5 integument MP:0010771 9.28 AR BRCA2 CDH1 HOXB13 KLF6 MIR146A

Drugs & Therapeutics for Prostate Cancer

PubMed Health treatment related to Prostate Cancer: 63

The possible treatment options for prostate cancer will depend on various factors. These include: how much the cells have changed (how aggressive the tumor is) how much the tumor has grown or spread (the stage of prostate cancer ) the man’s PSA levels individual factors such as the man’s age, how healthy he is otherwise, and how important the pros and cons are to him. Men who have high-risk prostate cancer will usually have their prostate surgically removed or treatment with radiotherapy. Radiotherapy can be done in two ways: from outside of the body (external radiotherapy) or from inside the body (internal radiotherapy , or brachytherapy ). The most common side effects of radiotherapy or removing the prostate gland are accidental leakage of urine (urinary incontinence ) and erection problems (impotence). External radiotherapy is especially likely to cause diarrhea , and in some cases inflammations in the bowel which may result in blood in the stool and cramps . If the tumor is small, only inside the prostate , and not aggressive (low-risk prostate cancer ), the following treatments are also possible: Active surveillance : Here the prostate cancer is simply monitored, and not treated, at first. This strategy is based on the fact that low-risk prostate cancer usually grows very slowly or doesn't grow at all. It is often found that the cancer has still not advanced even years after it was diagnosed. Instead of having treatment , the prostate is checked regularly. Treatment attempting to get rid of the cancer (curative treatment) is only started if the tumor starts growing. The advantage of this approach is that the side effects of surgery or radiotherapy can be avoided as long as the cancer does not grow. One possible disadvantage: If the cancer does progress, that is sometimes discovered too late. It may have already spread to other parts of the body by then (metastasis ). Knowing that you have cancer in your body can be distressing too. Watchful waiting : This strategy also starts by only monitoring the prostate cancer at first. But if the tumor starts growing, only the symptoms are treated, not the tumor itself (this is known as “palliative care ). This approach is mainly considered in older men, who may also have other medical problems. The risks and stress of surgery or radiotherapy could outweigh the possible benefits of this treatment . There is no “right” or “wrong” treatment decision for men who have low-risk prostate cancer . The strategy that one man chooses will mainly depend on his personal preferences and values. Some will feel it is more important to avoid side effects like impotence or incontinence as much as possible. Others will want to be very sure that the cancer has been removed, so they are willing to accept the risks associated with treatment. For more advanced stages of prostate cancer , there are several kinds of hormonal treatments and chemotherapies that aim to slow the growth.

Drugs for Prostate Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 865)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
Sildenafil Approved, Investigational Phase 4 139755-83-2, 171599-83-0 5212 135398744
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
Ofloxacin Approved Phase 4 82419-36-1 4583
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523 135413547
Zoledronic acid Approved Phase 4 118072-93-8 68740
Finasteride Approved Phase 4 98319-26-7 57363
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Lenograstim Approved, Investigational Phase 4 135968-09-1
Ranitidine Approved, Withdrawn Phase 4 66357-59-3, 82530-72-1, 66357-35-5 3001055 5039
Nitric Oxide Approved Phase 4 10102-43-9 145068
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1, 93107-08-5 2764
Acetaminophen Approved Phase 4 103-90-2 1983
Ondansetron Approved, Withdrawn Phase 4 99614-02-5 4595
Granisetron Approved, Investigational Phase 4 109889-09-0 3510 5284566
Risedronic acid Approved, Investigational Phase 4 105462-24-6 5245
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
Etidronic acid Approved Phase 4 2809-21-4, 7414-83-7 3305
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
Desflurane Approved Phase 4 57041-67-5 42113
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
Hydromorphone Approved, Illicit Phase 4 466-99-9, 71-68-1 5284570
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
Icodextrin Approved, Investigational Phase 4 337376-15-5
Clavulanic acid Approved, Vet_approved Phase 4 58001-44-8 5280980
Fosfomycin Approved Phase 4 23155-02-4 446987
Mepivacaine Approved, Vet_approved Phase 4 96-88-8, 1722-62-9 4062
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
Denosumab Approved Phase 4 615258-40-7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
Pamidronic acid Approved Phase 4 40391-99-9 4674
Naproxen Approved, Vet_approved Phase 4 22204-53-1 156391 1302
Ibuprofen Approved Phase 4 15687-27-1 3672
Droperidol Approved, Vet_approved Phase 4 548-73-2 3168
Pasireotide Approved Phase 4 396091-73-9 56841596 9941444
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605 16129706
Lactitol Approved, Investigational Phase 4 585-86-4 157355
Cabergoline Approved Phase 4 81409-90-7 54746
Abarelix Approved, Investigational, Withdrawn Phase 4 183552-38-7 21879626 16131215
Heparin, bovine Approved, Investigational, Withdrawn Phase 4 9005-49-6 22833565 9812414 772
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
Dexchlorpheniramine Experimental, Investigational Phase 4 25523-97-1 33036

Interventional clinical trials:

(show top 50) (show all 5513)
# Name Status NCT ID Phase Drugs
1 Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer Unknown status NCT02757365 Phase 4 aspirin;Levofloxacin
2 A Pilot Phase IV Study to Evaluate Variation in Bone Mineral Density, Lean and Fat Body Mass Index Measured by Dual-energy X-ray Absorptiometry in Patients With Prostate Cancer Without Bone Metastasis Treated With Degarelix Unknown status NCT03202381 Phase 4 Degarelix
3 MRI With a Lymph Node Specific Contrast Agent: an Alternative for CT-Scanning and Lymph Node Dissection in Patients With Prostate Cancer? Unknown status NCT00185029 Phase 4
4 METformin And Longevity (METAL): A Window of Opportunity Study Investigating Biological Effects of Metformin in Localised Prostate Cancer Unknown status NCT02511665 Phase 4 Metformin;Placebo
5 Intermittent Vs Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer Unknown status NCT00293670 Phase 4 Goserelin (Zoladex)
6 Prospective Evaluation of Truebeam STX Stereotactic Body Radiosurgery for Low and Intermediate Risk Prostate Cancer Unknown status NCT01581749 Phase 4
7 Comparison of Health Related Quality of Life and Other Clinical Parameters Between ThinSeed™ and OncoSeed™ for Permanent Low Dose Rate Implantation in Localized Prostate Cancer Unknown status NCT01379742 Phase 4
8 A Randomized, Double-blind, Placebo-controlled, Investigator Initiated Clinical Trial to Evaluate the Efficacy and Safety of Udenafil Dosed Once a Day in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy Unknown status NCT03142542 Phase 4 ZYDENA TAB.75mg(Udenafil 75mg);Placebo Oral Tablet
9 Post-Prostatectomy Erectile Dysfunction: Effect of Hyperbaric Oxygen Therapy Unknown status NCT00906269 Phase 4 Sildenafil therapy plus post-NSRRP HBO2T;Sildenafil therapy plus sham post-NSRRP HBO2T
10 Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer Completed NCT00219271 Phase 4 Zoledronic acid
11 A Randomized Double-Blind Parallel Group Study Comparing Casodex (or Generic Equivalent) 50mg Plus Placebo to Casodex (or Generic Equivalent) 50mg Plus Dutasteride 3.5mg Administered for 18 Months to Men With Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase Completed NCT00470834 Phase 4 dutasteride;placebo;bicalutamide
12 A Randomized, Open-label, Parallel-group Study, to Assess the Pharmocodynamic Effect on Dihydrotestosterone Regulated Gene Expression, Longitudinally and in a Dose Dependent Manner, of 0.5mg and 3.5mg Dutasteride Administered Orally Once Daily, for One Year in Men With Symptomatic Benign Prostatic Hyperplasia and During a Two Month Period Between Baseline and Radical Prostatectomy in Men With Biopsy-proven, Clinically Localized Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
13 A Multicenter, Single-arm, Open-label, Postmarketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure Completed NCT01977651 Phase 4 Enzalutamide
14 The Prognosis of Lipid Reprogramming With the HMG-CoA Reductase Inhibitor, Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients Completed NCT04776889 Phase 4 Rosuvastatin 20mg
15 A Pragmatic Randomised, Multicentre Trial Comparing 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases From Either Castration-resistant Prostate Cancer or Breast Cancer - The REaCT-BTA Study Completed NCT02721433 Phase 4 Pamidronate;Denosumab;Zoledronate
16 A Multi-center, Single Arm Study of Enzalutamide in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate Completed NCT02116582 Phase 4 Enzalutamide
18 A Phase IV Interventional Safety Study of ELIGARD® in Prostate Cancer Patients in Asia (ELIGANT) Completed NCT03035032 Phase 4 Leuprolide
19 A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety Completed NCT00434447 Phase 4 Zoledronic acid
20 Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer Completed NCT00391690 Phase 4 Zoledronic acid
21 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin Completed NCT02102646 Phase 4 Triptorelin
22 An Open-label, Single-Arm, Multicenter, Phase IV Trial to Evaluate the Safety of Firmagon® in Androgen Deprivation Therapy in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer Completed NCT02726009 Phase 4 Degarelix
23 Randomized, Double-Blind, Placebo-Controlled Trial Assessing The Efficacy And Safety Of Dutasteride At Improving Lower Urinary Tract Symptoms In Men With Clinically Localized Prostate Cancer Being Treated With Single-Dose Goserelin, Trans-Urethral Incision Of Prostate, And Interval Brachytherapy Completed NCT00805701 Phase 4 avodart;Placebo
24 Multicentre, Single Arm, Open Label, Non Controlled Phase IV Clinical Trial to Evaluate Safety of Cabazitaxel (Jevtana) in Combination With Oral Prednisone (or Prednisolone) for the Treatment of Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen Completed NCT02074137 Phase 4 CABAZITAXEL XRP6258;Prednisone;Prednisolone
25 A Multicenter, Open-label Study to Determine the Effect of iv. Zoledronic Acid on Pain and Quality of Life in Patients With Bone Metastases With or Without Skeletal Related Events (SRE) Resulting From Breast Cancer and Prostate Cancer Completed NCT00434317 Phase 4 Zoledronic acid
26 A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates Completed NCT00172016 Phase 4 Zoledronic acid
27 A Pilot Study on Endothelial Function and Cardiovascular Biomarkers in Prostate Cancer (PCa) Patients, With Pre-existing Cardiovascular Disease, Treated With Degarelix vs. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Completed NCT02475057 Phase 4 Degarelix (LHRH antagonist);LHRH agonist
28 Cabazitaxel in Combination With Prednisolone With Primary Prophylaxis With PEG-G-CSF for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer Completed NCT02441894 Phase 4 CABAZITAXEL XRP6258;PEG-G-CSF;Prednisolone;Dexchlorpheniramine or Diphenhydramine;Ranitidine;Metoclopramide, Granisetron, or Ondansetron;Dexamethasone
29 A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
30 An Open Randomised Trial to Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX Monotherapy Induced Gynaecomastia and/or Breast Pain in Prostate Cancer Patients Completed NCT00590213 Phase 4 Casodex 150mg
31 Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer Completed NCT00199485 Phase 4 Angelica Sinensis
32 A Phase IV, Multicenter, National, Non-comparative, Open-label Study of Cabazitaxel, Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Second-line Treatment of Patients With Metastatic Castration-resistant Prostate Cancer and After Failure of Docetaxel-based Chemotherapy. Descriptive Assessment of the Circulating Tumor Cells in This Context. Completed NCT01649635 Phase 4 CABAZITAXEL (XRP6258);Prednisone;Ciprofloxacin;G-CSF (Granulocyte colony-stimulating factor)
33 A Phase 4 Study of Zytiga in Poor-risk mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients Who Was Failed the First-line CAB (Combined Androgen Blockade) Therapy Completed NCT02405858 Phase 4 Abiraterone Acetate;Prednisolone
34 Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases Completed NCT00242554 Phase 4 Zoledronic acid
35 Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy. Completed NCT00237146 Phase 4 Zoledronic acid
36 A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer Completed NCT00220194 Phase 4 leuprolide acetate
37 A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men Who Are Candidates for or Undergoing Expectant Management Completed NCT00363311 Phase 4 Dutasteride;Matching placebo
38 A Prospective, Single-arm Multicenter Study to Evaluate Effect of Intravenous Zoledronic Acid on Bone Metabolism Given Over 4 Months in Patients With Prostate Cancer or Breast Cancer and Bone Metastasis Completed NCT00334139 Phase 4 Zoledronic Acid
39 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4 Zoledronic acid
40 Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases Completed NCT00219219 Phase 4 Zoledronic acid
41 Phase IV Study of Safety and Efficacy of Docetaxel in Combination With Prednisone in Advanced Hormone Refractory Prostate Cancer Treatment Completed NCT00280098 Phase 4 docetaxel
42 Effect of Isoflavones on Cognition, Quality of Life and Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Completed NCT00245518 Phase 4 Isoflavone;Placebos
43 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4 zoledronic acid
44 An Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis Completed NCT00035997 Phase 4 Zometa
45 PRospective, Multicenter Study to Evaluate Safety and Efficacy of Switching Treatments of Prostate Cancer Patients, Initially on Use of Monthly or Quarterly Goserelin Acetate (Zoladex®), to Semiannually Leuprorelin Acetate (Eligard®) Completed NCT05304169 Phase 4 Leuprorelin Acetate (Eligard® 45 mg).
46 A 12 Month Open Label Study of Serum Testosterone Recovery and PSA After Neo-Adjuvant Treatment With Eligard(TM) 22.5mg Used With Radiation Therapy in Patients With Early Prostate Cancer Completed NCT01136226 Phase 4 Eligard (TM)
47 Does Androgen Suppression Treatment In Prostate Cancer Reduce Myocardial Blood Flow Reserve? Completed NCT01230905 Phase 4
48 Non-comparative, Opened Multicenter Study to Assess the Efficacy and Safety of ELIGARD 22.5mg in the Treatment of Subjects With Prostate Cancer Completed NCT01511874 Phase 4 ELIGARD 22.5mg
49 A Randomized Phase IV Study Comparing Enzalutamide Versus Flutamide in Castration-resistant Prostate Cancer (CRPC) Patients Who Have Failed Combined Androgen Blockade Therapy With Bicalutamide Plus Androgen Deprivation Therapy (ADT) Completed NCT02918968 Phase 4 Enzalutamide;Flutamide
50 A Multicentric, Multinational (China and Russia), Randomised, Open, Controlled Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients Completed NCT01753297 Phase 4 Triptorelin 11.25 mg

Search NIH Clinical Center for Prostate Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Estradiol acetate
estradiol cypionate
estradiol valerate
Estramustine Phosphate Sodium
Estrogens, Conjugated (USP)
Estrogens, Esterified (USP)
Ethinyl Estradiol
etoposide phosphate
Goserelin Acetate
Leuprolide Acetate
Mitoxantrone Hydrochloride
polyestradiol phosphate
Sodium estrone sulfate
synthetic conjugated estrogens, A
synthetic conjugated estrogens, B

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Prostate Cancer cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: prostatic neoplasms

Genetic Tests for Prostate Cancer

Genetic tests related to Prostate Cancer:

# Genetic test Affiliating Genes
1 Familial Prostate Carcinoma 28
2 Malignant Tumor of Prostate 28 AR BRCA2 CDH1 CHEK2 KLF6 MAD1L1 MXI1 PTEN ZFHX3
3 Prostate Cancer, Somatic 28
4 Prostate Neoplasm 28
5 Prostate Cancer, Susceptibility to 28

Anatomical Context for Prostate Cancer

Organs/tissues related to Prostate Cancer:

FMA: Prostate
MalaCards : Prostate, Bone, Lymph Node, Breast, Bone Marrow, T Cells, Skin

Publications for Prostate Cancer

Articles related to Prostate Cancer:

(show top 50) (show all 54061)
# Title Authors PMID Year
-160C/A polymorphism in the E-cadherin gene promoter and risk of hereditary, familial and sporadic prostate cancer. 53 62 57 5
14961571 2004
KLF6, a candidate tumor suppressor gene mutated in prostate cancer. 53 62 57 5
11752579 2001
Mutation of the MXI1 gene in prostate cancer. 53 62 57 5
7773287 1995
The mutational landscape of lethal castration-resistant prostate cancer. 62 57 5
22722839 2012
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. 62 57 5
22610119 2012
Comprehensive genetic evaluation of common E-cadherin sequence variants and prostate cancer risk: strong confirmation of functional promoter SNP. 53 57 5
16189707 2005
Induced chromosomal proximity and gene fusions in prostate cancer. 53 62 57
19933109 2009
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. 53 62 57
17637754 2008
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. 53 62 57
17671502 2007
Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. 53 62 57
17377533 2007
A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. 53 62 5
17085682 2006
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. 53 62 57
16254181 2005
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. 53 62 5
15750593 2005
Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. 53 62 5
12474142 2003
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. 53 62 5
12415269 2002
BRCA2 mutation in a family with hereditary prostate cancer. 53 62 5
11170288 2001
Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. 62 5
33436325 2021
8q24 genetic variation and comprehensive haplotypes altering familial risk of prostate cancer. 62 5
32251286 2020
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer. 62 57
31969702 2020
IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. 62 57
29950727 2018
Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. 62 57
29808028 2018
Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. 62 57
28059767 2017
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. 62 57
28059768 2017
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. 62 57
27433846 2016
Identification of a novel germline SPOP mutation in a family with hereditary prostate cancer. 62 57
24796539 2014
G84E mutation in HOXB13 is firmly associated with prostate cancer risk: a meta-analysis. 62 5
24026887 2014
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. 62 57
23727860 2013
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. 62 57
23239736 2012
Germline mutations in HOXB13 and prostate-cancer risk. 62 5
22236224 2012
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. 62 57
21743467 2011
Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. 62 57
21602798 2011
The genomic complexity of primary human prostate cancer. 62 57
21307934 2011
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. 62 57
21289624 2011
Identification of a cell of origin for human prostate cancer. 62 57
20671189 2010
MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. 53 62 46
20332243 2010
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. 62 57
20220849 2010
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. 62 57
19767753 2009
Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. 62 57
19767754 2009
miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. 53 62 46
19584056 2009
miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. 53 62 46
19252524 2009
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. 62 57
19212411 2009
Androgen receptor is a tumor suppressor and proliferator in prostate cancer. 62 57
18723679 2008
Multiple newly identified loci associated with prostate cancer susceptibility. 62 57
18264097 2008
Multiple loci identified in a genome-wide association study of prostate cancer. 62 57
18264096 2008
Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. 62 57
18187659 2008
Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. 53 5
16609730 2006
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. 62 57
15988677 2005
Global histone modification patterns predict risk of prostate cancer recurrence. 62 57
15988529 2005
Comparison of microsatellites versus single-nucleotide polymorphisms in a genome linkage screen for prostate cancer-susceptibility Loci. 62 57
15514889 2004
CHEK2 is a multiorgan cancer susceptibility gene. 53 5
15492928 2004

Variations for Prostate Cancer

ClinVar genetic disease variations for Prostate Cancer:

5 (show top 50) (show all 873)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PRNCR1 NR_109833.1(PRNCR1):n.11999A>G SNV Association
979039 rs183373024 GRCh37: 8:128104117-128104117
GRCh38: 8:127091872-127091872
2 CASC19 SNV Association
979041 rs1428102803 GRCh37: 8:128205878-128205878
GRCh38: 8:127193633-127193633
3 CASC19 SNV Association
979042 rs138042437 GRCh37: 8:128208369-128208369
GRCh38: 8:127196124-127196124
4 CASC21 MICROSAT Association
979043 rs201885483 GRCh37: 8:128285409-128285412
GRCh38: 8:127273164-127273167
5 CASC21, CASC8 DUP Association
979044 rs201361304 GRCh37: 8:128337272-128337273
GRCh38: 8:127325027-127325028
6 CASC8 SNV Association
979045 rs78311688 GRCh37: 8:128479976-128479976
GRCh38: 8:127467731-127467731
7 AR NM_000044.6(AR):c.2599G>A (p.Val867Met) SNV Pathogenic
9806 rs137852564 GRCh37: X:66942818-66942818
GRCh38: X:67722976-67722976
8 AR NM_000044.6(AR):c.1301C>T (p.Ser434Phe) SNV Pathogenic
1167626 GRCh37: X:66766289-66766289
GRCh38: X:67546447-67546447
9 LOC109504725, AR NM_000044.6(AR):c.171GCA[11] (p.Gln69_Gln80del) MICROSAT Pathogenic
1556388 GRCh37: X:66765159-66765194
GRCh38: X:67545317-67545352
10 AR NM_000044.6(AR):c.2395C>G (p.Gln799Glu) SNV Pathogenic
9846 rs137852591 GRCh37: X:66941751-66941751
GRCh38: X:67721909-67721909
11 AR NM_000044.6(AR):c.161TGC[5] (p.Leu57dup) MICROSAT Pathogenic
958035 rs752055010 GRCh37: X:66765148-66765149
GRCh38: X:67545306-67545307
12 AR NM_000044.6(AR):c.814C>T (p.Leu272Phe) SNV Pathogenic
1205841 GRCh37: X:66765802-66765802
GRCh38: X:67545960-67545960
13 AR NM_000044.6(AR):c.1792A>G (p.Ser598Gly) SNV Pathogenic
1244234 GRCh37: X:66905875-66905875
GRCh38: X:67686033-67686033
14 AR NM_000044.6(AR):c.475G>A (p.Ala159Thr) SNV Pathogenic
492777 rs370215797 GRCh37: X:66765463-66765463
GRCh38: X:67545621-67545621
15 LOC109504725, AR NM_000044.6(AR):c.208C>T (p.Gln70Ter) SNV Pathogenic
1685531 GRCh37: X:66765196-66765196
GRCh38: X:67545354-67545354
16 AR NM_000044.6(AR):c.1025C>T (p.Pro342Leu) SNV Pathogenic
1685532 GRCh37: X:66766013-66766013
GRCh38: X:67546171-67546171
17 AR NM_000044.6(AR):c.1063G>C (p.Glu355Gln) SNV Pathogenic
1685533 GRCh37: X:66766051-66766051
GRCh38: X:67546209-67546209
18 AR NM_000044.6(AR):c.1175C>G (p.Pro392Arg) SNV Pathogenic
1685534 GRCh37: X:66766163-66766163
GRCh38: X:67546321-67546321
19 AR NM_000044.6(AR):c.1195T>C (p.Trp399Arg) SNV Pathogenic
1685535 GRCh37: X:66766183-66766183
GRCh38: X:67546341-67546341
20 AR NM_000044.6(AR):c.1208C>T (p.Ala403Val) SNV Pathogenic
1685537 GRCh37: X:66766196-66766196
GRCh38: X:67546354-67546354
21 AR NM_000044.6(AR):c.1644G>T (p.Leu548Phe) SNV Pathogenic
1685538 GRCh37: X:66863125-66863125
GRCh38: X:67643283-67643283
22 AR NM_000044.6(AR):c.1651G>C (p.Asp551His) SNV Pathogenic
1685539 GRCh37: X:66863132-66863132
GRCh38: X:67643290-67643290
23 AR NM_000044.6(AR):c.2184C>G (p.Asn728Lys) SNV Pathogenic
1685540 GRCh37: X:66937330-66937330
GRCh38: X:67717488-67717488
24 MAD1L1 NM_001013836.2(MAD1L1):c.175C>T (p.Arg59Cys) SNV Pathogenic
6920 rs121908982 GRCh37: 7:2265161-2265161
GRCh38: 7:2225526-2225526
25 KLF6 NM_001300.6(KLF6):c.346T>C (p.Ser116Pro) SNV Pathogenic
7569 rs121909139 GRCh37: 10:3824163-3824163
GRCh38: 10:3781971-3781971
26 KLF6 NM_001300.6(KLF6):c.410C>A (p.Ser137Ter) SNV Pathogenic
7570 rs121909140 GRCh37: 10:3824099-3824099
GRCh38: 10:3781907-3781907
27 KLF6 NM_001300.6(KLF6):c.368C>A (p.Ala123Asp) SNV Pathogenic
7571 rs121909141 GRCh37: 10:3824141-3824141
GRCh38: 10:3781949-3781949
28 KLF6 NM_001300.6(KLF6):c.190T>C (p.Trp64Arg) SNV Pathogenic
7572 rs121909142 GRCh37: 10:3824319-3824319
GRCh38: 10:3782127-3782127
29 KLF6 NM_001300.6(KLF6):c.506T>C (p.Leu169Pro) SNV Pathogenic
7573 rs121909143 GRCh37: 10:3824003-3824003
GRCh38: 10:3781811-3781811
30 AR NM_000044.6(AR):c.1943G>A (p.Ser648Asn) SNV Pathogenic
9809 rs137852584 GRCh37: X:66931301-66931301
GRCh38: X:67711459-67711459
31 AR NM_000044.6(AR):c.2191G>A (p.Val731Met) SNV Pathogenic
9817 rs137852571 GRCh37: X:66937337-66937337
GRCh38: X:67717495-67717495
32 AR NM_000044.6(AR):c.2632A>G (p.Thr878Ala) SNV Pathogenic
9831 rs137852578 GRCh37: X:66943552-66943552
GRCh38: X:67723710-67723710
33 AR NM_000044.6(AR):c.2633C>G (p.Thr878Ser) SNV Pathogenic
9833 rs137852580 GRCh37: X:66943553-66943553
GRCh38: X:67723711-67723711
34 AR NM_000044.6(AR):c.2623C>T (p.His875Tyr) SNV Pathogenic
9834 rs137852581 GRCh37: X:66943543-66943543
GRCh38: X:67723701-67723701
35 AR NM_000044.6(AR):c.2708A>G (p.Gln903Arg) SNV Pathogenic
9835 rs137852582 GRCh37: X:66943628-66943628
GRCh38: X:67723786-67723786
36 AR NM_000044.6(AR):c.2164G>A (p.Ala722Thr) SNV Pathogenic
9836 rs137852583 GRCh37: X:66931522-66931522
GRCh38: X:67711680-67711680
37 AR NM_000044.6(AR):c.2180G>T (p.Arg727Leu) SNV Pathogenic
9849 rs137852593 GRCh37: X:66937326-66937326
GRCh38: X:67717484-67717484
38 MXI1 NM_130439.3(MXI1):c.623del (p.Lys208fs) DEL Pathogenic
9534 GRCh37: 10:112039740-112039740
GRCh38: 10:110279982-110279982
39 ZFHX3-AS1, ZFHX3 NM_006885.4(ZFHX3):c.10142_10165del (p.Arg3381_Gln3388del) DEL Pathogenic
18167 rs727502780 GRCh37: 16:72822010-72822033
GRCh38: 16:72788111-72788134
40 PTEN NM_000314.8(PTEN):c.761_765del (p.Lys254fs) DEL Pathogenic
7830 rs606231169 GRCh37: 10:89717735-89717739
GRCh38: 10:87957978-87957982
41 PTEN NM_000314.8(PTEN):c.564T>A (p.Tyr188Ter) SNV Pathogenic
7831 rs606231170 GRCh37: 10:89711946-89711946
GRCh38: 10:87952189-87952189
42 PTEN NM_000314.8(PTEN):c.253+2T>A SNV Pathogenic
468676 rs1224040268 GRCh37: 10:89690848-89690848
GRCh38: 10:87931091-87931091
43 PTEN NM_000314.8(PTEN):c.860C>G (p.Ser287Ter) SNV Pathogenic
216987 rs863224909 GRCh37: 10:89720709-89720709
GRCh38: 10:87960952-87960952
44 MXI1 NM_130439.3(MXI1):c.552+2T>C SNV Pathogenic
9535 rs387906417 GRCh37: 10:112039054-112039054
GRCh38: 10:110279296-110279296
45 MXI1 NM_130439.3(MXI1):c.656A>C (p.Glu219Ala) SNV Pathogenic
9536 rs137852603 GRCh37: 10:112039775-112039775
GRCh38: 10:110280017-110280017
46 POLK NM_016218.6(POLK):c.464T>C (p.Phe155Ser) SNV Pathogenic
218230 rs1554059550 GRCh37: 5:74869618-74869618
GRCh38: 5:75573793-75573793
47 POLK NM_016218.6(POLK):c.410C>T (p.Ser137Phe) SNV Pathogenic
218231 rs863225454 GRCh37: 5:74869564-74869564
GRCh38: 5:75573739-75573739
48 POLK NM_016218.6(POLK):c.1324C>T (p.Leu442Phe) SNV Pathogenic
218218 rs1554062789 GRCh37: 5:74886233-74886233
GRCh38: 5:75590408-75590408
49 POLK NM_016218.6(POLK):c.461G>A (p.Gly154Glu) SNV Pathogenic
218232 rs749804502 GRCh37: 5:74869615-74869615
GRCh38: 5:75573790-75573790
50 POLK NM_016218.6(POLK):c.512T>C (p.Phe171Ser) SNV Pathogenic
218233 rs1554059573 GRCh37: 5:74869666-74869666
GRCh38: 5:75573841-75573841

UniProtKB/Swiss-Prot genetic disease variations for Prostate Cancer:

73 (show all 19)
# Symbol AA change Variation ID SNP ID
1 CHEK2 p.Arg180Cys VAR_019103 rs77130927
2 CHEK2 p.Arg181Cys VAR_019104 rs137853010
3 CHEK2 p.Arg181His VAR_019105 rs121908701
4 CHEK2 p.Glu239Lys VAR_019106 rs121908702
5 CHEK2 p.Glu64Lys VAR_019107 rs141568342
6 CHEK2 p.Arg145Pro VAR_019108 rs587781667
7 CHEK2 p.Gly167Arg VAR_019109 rs72552322
8 CHEK2 p.Arg180His VAR_019110 rs137853009
9 CHEK2 p.Thr323Pro VAR_019113 rs750984976
10 CHEK2 p.Thr476Lys VAR_019115
11 EPHB2 p.Arg199His VAR_032853 rs201754821
12 EPHB2 p.Ala279Ser VAR_032854 rs35882952
13 EPHB2 p.Val650Ala VAR_032855 rs142173175
14 EPHB2 p.His679Asn VAR_032856
15 EPHB2 p.Met883Val VAR_032857 rs372653137
16 EPHB2 p.Ile909Met VAR_032858
17 HOXB13 p.Gly84Glu VAR_071866 rs138213197
18 MXI1 p.Glu152Ala VAR_004499 rs137852603
19 PTEN p.Met134Leu VAR_007469

Cosmic variations for Prostate Cancer:

8 (show top 50) (show all 43800)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87273255 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.8849G>A p.R2950H 16:72793833-72793833 42
2 COSM87278310 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.5650G>T p.E1884* 16:72797032-72797032 42
3 COSM102023521 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.598C>T p.R200* 16:72889839-72889839 42
4 COSM102020948 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.791C>A p.S264* 16:72812035-72812035 42
5 COSM102027229 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.2908G>T p.E970* 16:72797032-72797032 42
6 COSM149310968 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.5893C>T p.Q1965* 16:72796789-72796789 42
7 COSM87289963 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.2728G>A p.E910K 16:72950957-72950957 42
8 COSM87277276 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.2986A>T p.K996* 16:72950699-72950699 42
9 COSM102022171 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.6107G>A p.R2036H 16:72793833-72793833 42
10 COSM102025889 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.244A>T p.K82* 16:72950699-72950699 42
11 COSM149331699 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.5114C>G p.S1705* 16:72797568-72797568 42
12 COSM87287233 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.4819C>T p.Q1607* 16:72797863-72797863 42
13 COSM87296500 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.5114C>G p.S1705* 16:72797568-72797568 42
14 COSM149269669 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.3340C>T p.R1114* 16:72889839-72889839 42
15 COSM87271970 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.3533C>A p.S1178* 16:72812035-72812035 42
16 COSM149281678 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.5650G>T p.E1884* 16:72797032-72797032 42
17 COSM149265910 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.8849G>A p.R2950H 16:72793833-72793833 42
18 COSM87274612 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.3340C>T p.R1114* 16:72889839-72889839 42
19 COSM102031608 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.-23-8776C>G p.? 16:72959741-72959741 42
20 COSM149307401 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.4819C>T p.Q1607* 16:72797863-72797863 42
21 COSM87288892 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.5893C>T p.Q1965* 16:72796789-72796789 42
22 COSM149287761 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.6445C>T p.R2149C 16:72796237-72796237 42
23 COSM102037736 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.2077C>T p.Q693* 16:72797863-72797863 42
24 COSM149262752 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.3533C>A p.S1178* 16:72812035-72812035 42
25 COSM87281944 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.405C>G p.Y135* 16:72959741-72959741 42
26 COSM102047721 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.2372C>G p.S791* 16:72797568-72797568 42
27 COSM102029776 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.3703C>T p.R1235C 16:72796237-72796237 42
28 COSM87280241 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.6445C>T p.R2149C 16:72796237-72796237 42
29 COSM149314230 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.2728G>A p.E910K 16:72950957-72950957 42
30 COSM149278210 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.2986A>T p.K996* 16:72950699-72950699 42
31 COSM102039151 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.3151C>T p.Q1051* 16:72796789-72796789 42
32 COSM102040223 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.-15G>A p.? 16:72950957-72950957 42
33 COSM149292073 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.405C>G p.Y135* 16:72959741-72959741 42
34 COSM89894202 YES1 prostate,NS,carcinoma,adenocarcinoma c.119C>G p.S40* 18:756709-756709 42
35 COSM136834926 YES1 prostate,NS,carcinoma,adenocarcinoma c.590-1G>T p.? 18:745858-745858 42
36 COSM152021810 YES1 prostate,NS,carcinoma,adenocarcinoma c.575-1G>T p.? 18:745858-745858 42
37 COSM152022004 YES1 prostate,NS,carcinoma,adenocarcinoma c.119C>G p.S40* 18:756709-756709 42
38 COSM136836036 YES1 prostate,NS,carcinoma,adenocarcinoma c.134C>G p.S45* 18:756709-756709 42
39 COSM89892790 YES1 prostate,NS,carcinoma,adenocarcinoma c.575-1G>T p.? 18:745858-745858 42
40 COSM104882949 XPO1 prostate,NS,carcinoma,adenocarcinoma c.1259T>C p.M420T 2:61493040-61493040 42
41 COSM104239299 XPO1 prostate,NS,carcinoma,adenocarcinoma c.1384G>T p.V462F 2:61492915-61492915 42
42 COSM101975701 XPO1 prostate,NS,carcinoma,adenocarcinoma c.1711G>A p.E571K 2:61492337-61492337 42
43 COSM101977073 XPO1 prostate,NS,carcinoma,adenocarcinoma c.1259T>C p.M420T 2:61493040-61493040 42
44 COSM101976154 XPO1 prostate,NS,carcinoma,adenocarcinoma c.2468T>G p.F823C 2:61485808-61485808 42
45 COSM104881227 XPO1 prostate,NS,carcinoma,adenocarcinoma c.1711G>A p.E571K 2:61492337-61492337 42
46 COSM104238027 XPO1 prostate,NS,carcinoma,adenocarcinoma c.3101T>G p.F1034C 2:61478935-61478935 42
47 COSM104236414 XPO1 prostate,NS,carcinoma,adenocarcinoma c.1259T>C p.M420T 2:61493040-61493040 42
48 COSM101979599 XPO1 prostate,NS,carcinoma,adenocarcinoma c.1384G>T p.V462F 2:61492915-61492915 42
49 COSM101981883 XPO1 prostate,NS,carcinoma,adenocarcinoma c.1098T>A p.F366L 2:61494041-61494041 42
50 COSM104888806 XPO1 prostate,NS,carcinoma,adenocarcinoma c.1098T>A p.F366L 2:61494041-61494041 42

Copy number variations for Prostate Cancer from CNVD:

6 (show top 50) (show all 2798)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13313 1 1 117600000 Copy number ALX3 Prostate cancer
2 13314 1 1 117600000 Copy number SORT1 Prostate cancer
3 13346 1 1 125000000 Copy number Prostate cancer
4 14053 1 1036980 47620504 Gain Prostate cancer
5 14413 1 107915304 108309068 Gain or loss VAV3 Prostate cancer
6 14604 1 109594163 109619901 Gain or loss CELSR2 Prostate cancer
7 14862 1 110683467 110690826 Gain or loss RBM15 Prostate cancer
8 14889 1 11089178 11245151 Gain or loss MTOR Prostate cancer
9 14967 1 111600000 117600000 Loss ST7L Prostate cancer
10 15009 1 111800000 117800000 Loss Prostate cancer
11 15029 1 111886577 112057624 Gain or loss RAP1A Prostate cancer
12 15125 1 112811562 112865428 Gain or loss WNT2B Prostate cancer
13 15163 1 113045271 113051548 Gain or loss RHOC Prostate cancer
14 15175 1 113054138 113059473 Gain or loss PPM1J Prostate cancer
15 15247 1 113734997 114030068 Gain or loss MAGI3 Prostate cancer
16 15337 1 114736921 114855304 Gain or loss TRIM33 Prostate cancer
17 15399 1 115048600 115061038 Gain or loss NRAS Prostate cancer
18 15451 1 115630059 115682380 Gain or loss NGF Prostate cancer
19 15536 1 11657123 11674265 Gain or loss MAD2L2 Prostate cancer
20 15926 1 120255698 120413799 Gain or loss NOTCH2 Prostate cancer
21 16475 1 125000000 249250621 Copy number Prostate cancer
22 17314 1 142400000 148000000 Gain PIAS3 Prostate cancer
23 17468 1 142916565 153594838 Gain Prostate cancer
24 17469 1 142916565 240032059 Gain Prostate cancer
25 17551 1 143388229 143787436 Gain or loss PDE4DIP Prostate cancer
26 18160 1 144225552 144227256 Gain or loss GNRHR2 Prostate cancer
27 18188 1 144287344 144297903 Gain or loss PIAS3 Prostate cancer
28 18365 1 145093308 145110753 Gain or loss PRKAB2 Prostate cancer
29 18417 1 145479805 145564639 Gain or loss BCL9 Prostate cancer
30 19025 1 148178855 148249310 Gain or loss OTUD7B Prostate cancer
31 19186 1 149048809 149115810 Gain or loss ARNT Prostate cancer
32 19410 1 150112683 150148737 Gain or loss THEM4 Prostate cancer
33 20574 1 153201397 153213464 Copy number SHC1 Prostate cancer
34 20586 1 153201397 153213464 Gain or loss SHC1 Prostate cancer
35 20657 1 153424923 153429324 Gain or loss MUC1 Prostate cancer
36 20781 1 154291228 154296003 Gain or loss LAMTOR2 Prostate cancer
37 20798 1 154391405 163508931 Loss Prostate cancer
38 20896 1 155003897 155037233 Gain or loss PRCC Prostate cancer
39 20918 1 155052165 155118266 Gain or loss NTRK1 Prostate cancer
40 20933 1 155077288 155095290 Gain or loss INSRR Prostate cancer
41 21138 1 15689910 15723971 Gain or loss CASP9 Prostate cancer
42 21233 1 157441133 157442914 Gain or loss ACKR1 Prostate cancer
43 21256 1 157526129 157544638 Gain or loss FCER1A Prostate cancer
44 21414 1 158441750 158451786 Gain or loss PEA15 Prostate cancer
45 21441 1 158579686 158595366 Gain or loss NCSTN Prostate cancer
46 21729 1 160868851 161016871 Gain or loss DDR2 Prostate cancer
47 21782 1 161466500 164524500 Gain Prostate cancer
48 21904 1 162795560 163082934 Gain or loss PBX1 Prostate cancer
49 21948 1 16323418 16355151 Gain or loss EPHA2 Prostate cancer
50 22793 1 168899936 168975165 Gain or loss PRRX1 Prostate cancer

Expression for Prostate Cancer

LifeMap Discovery
Genes differentially expressed in tissues of Prostate Cancer patients vs. healthy controls: 35 (show top 50) (show all 189)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 KLK3 kallikrein related peptidase 3 Bone + 7.74 0.000
2 KLK2 kallikrein related peptidase 2 Bone + 7.14 0.000
3 LTF lactotransferrin Bone - 6.47 0.000
4 DEFA4 defensin alpha 4 Bone - 6.27 0.000
5 S100A8 S100 calcium binding protein A8 Bone - 6.25 0.000
6 S100A9 S100 calcium binding protein A9 Bone - 6.18 0.000
7 HBD hemoglobin subunit delta Bone - 6.02 0.000
8 CAMP cathelicidin antimicrobial peptide Bone - 5.90 0.000
9 ALAS2 5'-aminolevulinate synthase 2 Bone - 5.74 0.000
10 FOLH1 folate hydrolase 1 Bone + 5.70 0.000
11 MPO myeloperoxidase Bone - 5.70 0.000
12 GOLM1 golgi membrane protein 1 Bone + 5.64 0.000
13 MS4A3 membrane spanning 4-domains A3 Bone - 5.61 0.000
14 CEACAM8 CEA cell adhesion molecule 8 Bone - 5.56 0.000
15 SLC4A1 solute carrier family 4 member 1 (Diego blood group) Bone - 5.56 0.000
16 MNDA myeloid cell nuclear differentiation antigen Bone - 5.53 0.000
17 IKZF4 IKAROS family zinc finger 4 Prostate - 5.49 0.026
18 S100A12 S100 calcium binding protein A12 Bone - 5.49 0.000
19 CA1 carbonic anhydrase 1 Bone - 5.48 0.000
20 EPB42 erythrocyte membrane protein band 4.2 Bone - 5.47 0.000
21 CYP3A5 cytochrome P450 family 3 subfamily A member 5 Prostate - 5.46 0.013
22 PPBP pro-platelet basic protein Bone - 5.45 0.000
23 LCN2 lipocalin 2 Bone - 5.45 0.000
24 PRG2 proteoglycan 2, pro eosinophil major basic protein Bone - 5.35 0.000
25 FOLH1B folate hydrolase 1B (pseudogene) Bone + 5.31 0.000
26 RNASE2 ribonuclease A family member 2 Bone - 5.31 0.000
27 KIRREL3 kirre like nephrin family adhesion molecule 3 Prostate - 5.28 0.024
28 CYP3A4 cytochrome P450 family 3 subfamily A member 4 Prostate - 5.18 0.010
29 BPI bactericidal permeability increasing protein Bone - 5.11 0.000
30 GYPA glycophorin A (MNS blood group) Bone - 5.04 0.000
31 ELANE elastase, neutrophil expressed Bone - 5.04 0.000
32 AHSP alpha hemoglobin stabilizing protein Bone - 5.01 0.000
33 CTSG cathepsin G Bone - 4.89 0.000
34 CLC Charcot-Leyden crystal galectin Bone - 4.89 0.000
35 GYPB glycophorin B (MNS blood group) Bone - 4.88 0.000
36 WIF1 WNT inhibitory factor 1 Prostate - 4.87 0.008
37 LYZ lysozyme Bone - 4.83 0.000
38 CA2 carbonic anhydrase 2 Bone - 4.75 0.000
39 NKX3-1 NK3 homeobox 1 Bone + 4.70 0.000
40 DUOXA1 dual oxidase maturation factor 1 Prostate - 4.69 0.010
41 RHD Rh blood group D antigen Bone - 4.69 0.000
42 ARG1 arginase 1 Bone - 4.67 0.000
43 CD177 CD177 molecule Prostate - 4.67 0.014
44 PF4 platelet factor 4 Bone - 4.66 0.000
45 SPTA1 spectrin alpha, erythrocytic 1 Bone - 4.65 0.000
46 FXYD3 FXYD domain containing ion transport regulator 3 Bone + 4.62 0.000
47 PDLIM5 PDZ and LIM domain 5 Bone + 4.54 0.000
48 LAMB3 laminin subunit beta 3 Prostate - 4.53 0.014
49 SRGN serglycin Bone - 4.49 0.000
50 ACP3 acid phosphatase 3 Bone + 4.48 0.000
Search GEO for disease gene expression data for Prostate Cancer.

Pathways for Prostate Cancer

Pathways related to Prostate Cancer according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
11.73 TP53 CHEK2 BRCA2
4 11.71 TP53 PTEN POLK
5 11.69 PTEN MAD1L1 CDH1
6 11.67 PTEN POLK MIR145
Show member pathways
11.59 TP53 CHEK2 BRCA2
9 11.56 TP53 CHEK2 BRCA2
10 11.47 TP53 PTEN MIRLET7C
Show member pathways
11.35 MIR222 MIR221 MIR17 MIR145
12 11.08 TP53 PTEN CHEK2
13 10.94 TP53 PTEN CHEK2
14 10.93 TP53 MIR222 MIR221 MIR21 MIR17 MIR145
15 10.46 TP53 CDH1
16 10.18 CHEK2 TP53

GO Terms for Prostate Cancer

Cellular components related to Prostate Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.53 MIRLET7C MIR222 MIR221 MIR21 MIR205 MIR17
2 extracellular vesicle GO:1903561 9.35 MIRLET7C MIR222 MIR221 MIR21 MIR17

Biological processes related to Prostate Cancer according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of DNA-templated transcription GO:0045893 10.49 ZFHX3 TP53 KLF6 CHEK2 CDH1 BRCA2
2 miRNA-mediated gene silencing GO:0035195 10.25 MIR145 MIR146A MIR17 MIR205 MIR21 MIR221
3 positive regulation of gene expression GO:0010628 10.24 TP53 MIR21 MIR205 MIR17 MIR146A AR
4 cellular response to hypoxia GO:0071456 10.1 TP53 PTEN MIR17 MIR146A
5 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 10.09 TP53 CHEK2 BRCA2
6 negative regulation of cell migration GO:0030336 10.07 PTEN MIR21 MIR205 MIR145 CDH1
7 negative regulation of gene expression GO:0010629 10.04 TP53 MIR21 MIR205 MIR17 MIR146A
8 cellular response to gamma radiation GO:0071480 10 TP53 MIR21 CHEK2
9 response to gamma radiation GO:0010332 9.98 TP53 CHEK2 BRCA2
10 prostate gland growth GO:0060736 9.96 PTEN AR
11 negative regulation of protein kinase B signaling GO:0051898 9.96 PTEN MIR146A MIR145
12 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.95 PTEN MIR221 MIR21 MIR205
13 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.95 TP53 CHEK2 BRCA2
14 negative regulation of inflammatory response GO:0050728 9.85 MIR222 MIR221 MIR205 MIR146A MIR145
15 positive regulation of epithelial to mesenchymal transition GO:0010718 9.83 MIR222 MIR221 MIR21
16 negative regulation of endothelial cell proliferation GO:0001937 9.8 MIR21 MIR205 MIR146A
17 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.79 MIR222 MIR221 MIR146A
18 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.78 MIR221 MIR205 MIR146A
19 negative regulation of angiogenesis GO:0016525 9.77 MIR222 MIR21 MIR205 MIR146A MIR145
20 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.71 MIR221 MIR21 MIR146A
21 negative regulation of vascular endothelial growth factor production GO:1904046 9.69 MIR205 MIR17 MIR146A
22 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.63 MIR17 MIR21
23 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.59 MIR222 MIR221
24 positive regulation of cellular response to hypoxia GO:1900039 9.58 MIR145 MIR21
25 negative regulation of cell adhesion molecule production GO:0060354 9.58 MIR222 MIR221 MIR146A
26 positive regulation of Schwann cell migration GO:1900149 9.57 MIR221 MIR222
27 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.56 MIR221 MIR222
28 positive regulation of metalloendopeptidase activity GO:1904685 9.5 MIR21 MIR205 MIR17
29 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.49 MIR222 MIR221
30 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.43 MIR222 MIR221 MIR146A
31 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.35 MIR222 MIR221 MIR21 MIR17 MIR146A
32 negative regulation of interleukin-21 production GO:0032705 9.33 MIR222 MIR221 MIR21
33 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.17 MIR222 MIR221 MIR21 MIR205 MIR17 MIR146A

Molecular functions related to Prostate Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.5 TP53 MIR21 MIR205 MIR17 MIR146A MIR145
2 mRNA base-pairing translational repressor activity GO:1903231 9.23 MIRLET7C MIR222 MIR221 MIR21 MIR205 MIR17

Sources for Prostate Cancer

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....